Document Detail

Relation of C-reactive protein level and long-term risk of death or myocardial infarction following percutaneous coronary intervention with a sirolimus-eluting stent.
MedLine Citation:
PMID:  16923447     Owner:  NLM     Status:  MEDLINE    
Previous observations in the bare metal stent (BMS) era have demonstrated an association between a high preprocedural C-reactive protein (CRP) level and an increased incidence of death or myocardial infarction after percutaneous coronary intervention (PCI). We hypothesized that PCI with sirolimus-eluting stents (SESs) would result in a smaller increase in CRP compared with BMSs and that a high CRP level before PCI would be associated with a higher incidence of death or myocardial infarction at 12 months, regardless of the type of stent implanted. We analyzed patients who underwent PCI with stenting at the Cleveland Clinic Foundation. Patients who received BMSs and SESs were analyzed separately by categorizing them into low and high CRP groups based on whether their CRP level before PCI was above or below the median for each group. The increase in CRP that occurred with PCI was termed DeltaCRP. In total, 652 patients were included in the analysis. Median DeltaCRP was smaller in the SES group than in the BMS group (1.5 vs 0.7 mg/L, p = 0.009). In the BMS group, patients with a CRP level above the median before PCI had a higher incidence of 12-month death or myocardial infarction compared with patients with a CRP level below the median (11.3% vs 1.6%, p = 0.002). The same relation was present in the SES group, i.e., patients with a higher CRP level had a higher incidence of 12-month death or myocardial infarction compared with patients with a low CRP level (6.3% vs 1.0%, p = 0.005) and a higher 12-month mortality (5.2% vs 0%, p = 0.001). Multivariate logistic regression analysis demonstrated that the CRP level above the median before PCI was associated with a higher 12-month incidence of death or myocardial infarction, independent of the type of stent used, or DeltaCRP. In conclusion, PCI in the SES era causes a smaller increase in CRP compared with the BMS era. A high CRP level before PCI is independently associated with a higher risk of long-term death or myocardial infarction. This finding was present in the BMS and SES groups and highlights the need for aggressive risk-factor modification after PCI.
Juhana Karha; Anthony A Bavry; Vivek Rajagopal; Mark R Henderson; Stephen G Ellis; Sorin J Brener
Related Documents :
24445697 - Cardiac structural and functional changes in old elderly patients with obstructive slee...
24582837 - Assessment of myocardial viability and left ventricular function in patients supported ...
23367457 - Assessment of hemodynamic load components affecting optimization of cardiac resynchroni...
18813037 - Cardiac risk of noncardiac surgery after percutaneous coronary intervention with drug-e...
8281677 - Ventricular proarrhythmic effects of ventricular cycle length and shock strength in a s...
18617317 - Hyperkalemia induced failure of pacemaker capture and sensing.
Publication Detail:
Type:  Comparative Study; Journal Article     Date:  2006-07-10
Journal Detail:
Title:  The American journal of cardiology     Volume:  98     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  2006 Sep 
Date Detail:
Created Date:  2006-08-22     Completed Date:  2006-09-28     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  616-8     Citation Subset:  AIM; IM    
Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Biological Markers / blood
Blood Vessel Prosthesis Implantation / instrumentation*
C-Reactive Protein / metabolism*
Coated Materials, Biocompatible*
Coronary Disease* / blood,  mortality,  surgery
Follow-Up Studies
Immunosuppressive Agents / therapeutic use
Middle Aged
Myocardial Infarction* / blood,  epidemiology
Ohio / epidemiology
Prospective Studies
Risk Factors
Sirolimus / therapeutic use*
Survival Rate / trends
Time Factors
Reg. No./Substance:
0/Biological Markers; 0/Coated Materials, Biocompatible; 0/Immunosuppressive Agents; 53123-88-9/Sirolimus; 9007-41-4/C-Reactive Protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effect of enhanced external counterpulsation on resting oxygen uptake in patients having previous co...
Next Document:  Comparison of functional status after coronary artery bypass grafting in patients with and without d...